Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational study
暂无分享,去创建一个
M. Davidovits | Y. Levy-Shraga | D. Tiosano | A. Zung | A. Brener | R. Cleper | D. Strich | Rachel Bello | S. Levi | Shoshana Gal | Y Lebenthal | Yael Borovitz | Ravit Regev | David Gillis | Ariel Tenenbaum | Zvi Zadik | Leonid Zeitlin
[1] G. Baroncelli,et al. Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries , 2023, Frontiers in Endocrinology.
[2] C. Audrain,et al. Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone , 2022, Orphanet Journal of Rare Diseases.
[3] F. Di Serio,et al. Determination of iFGF23 Upper Reference Limits (URL) in healthy pediatric population, for its better correct use , 2022, Frontiers in Endocrinology.
[4] J. Salles,et al. Growth hormone treatment improves final height in children with X-linked hypophosphatemia , 2022, Orphanet journal of rare diseases.
[5] F. Glorieux,et al. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia , 2022, The Journal of clinical endocrinology and metabolism.
[6] A. Siafarikas,et al. Clinical practice guidelines for paediatric X‐linked hypophosphataemia in the era of burosumab , 2022, Journal of paediatrics and child health.
[7] M. Sharafinski,et al. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets , 2022, Pediatric Nephrology.
[8] M. Whyte,et al. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia , 2021, The Journal of clinical endocrinology and metabolism.
[9] S. Mora,et al. X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management , 2021, Frontiers in Endocrinology.
[10] W. Högler,et al. Monitoring response to conventional treatment in children with XLH: Value of ALP and Rickets Severity Score (RSS) in a real world setting. , 2021, Bone.
[11] Y. Seino,et al. Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets , 2021, Journal of pediatric endocrinology & metabolism : JPEM.
[12] L. Zeitlin,et al. Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy , 2021, Therapeutic advances in endocrinology and metabolism.
[13] F. Glorieux,et al. Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia , 2021, Calcified Tissue International.
[14] F. Santos Rodríguez. X-Linked Hypophosphataemic Rickets and Growth , 2020, Advances in Therapy.
[15] J. S. San Martin,et al. Growth Curves for Children with X-linked Hypophosphatemia , 2019, The Journal of clinical endocrinology and metabolism.
[16] L. Rejnmark,et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia , 2019, Nature Reviews Nephrology.
[17] J. S. San Martin,et al. Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score. , 2019, Bone.
[18] K. White,et al. Pharmacological management of X-linked hypophosphataemia. , 2018, British journal of clinical pharmacology.
[19] M. Collins. Burosumab: At Long Last, an Effective Treatment for FGF23‐Associated Hypophosphatemia , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] D. Haffner,et al. Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets , 2018, Pediatric Nephrology.
[21] J. Salles,et al. Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR). , 2017, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[22] M. Kuro-o,et al. FGF23-αKlotho as a paradigm for a kidney-bone network. , 2017, Bone.
[23] F. Glorieux,et al. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. , 2015, The Journal of clinical endocrinology and metabolism.
[24] S. Ellard,et al. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment , 2012, Pediatric Nephrology.
[25] D. Fischer,et al. Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. , 2011, The Journal of clinical endocrinology and metabolism.
[26] D. Haffner,et al. Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets , 2011, Pediatric Nephrology.
[27] D. Haffner,et al. Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. , 2004, Pediatrics.
[28] O. Mäkitie,et al. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. , 2003, The Journal of clinical endocrinology and metabolism.
[29] G. Saggese,et al. Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. , 2001, The Journal of pediatrics.
[30] B. Manaster,et al. Radiographic scoring method for the assessment of the severity of nutritional rickets. , 2000, Journal of tropical pediatrics.
[31] R. B. Payne,et al. Renal Tubular Reabsorption of Phosphate (TmP/GFR): Indications and Interpretation , 1998, Annals of clinical biochemistry.
[32] OUP accepted manuscript , 2021, Nephrology Dialysis Transplantation.